Actimed Therapeutics Partners with Mankind Pharma for Cachexia Treatment in South Asia

Strategic partnership and regional impact  

On November 21, 2025, Actimed Therapeutics announced its licensing pact with Mankind Pharma, one of India’s leading pharmaceutical companies and a shareholder in Actimed. The agreement provides Mankind exclusive territorial rights across India, Bangladesh, Bhutan, Nepal, Sri Lanka, and Myanmar. It includes Actimed’s patents and proprietary know-how, enabling Mankind to manufacture and market therapies under its own trademarks. Cachexia, a debilitating condition affecting cancer patients, is estimated to contribute to nearly 20% of cancer-related deaths. Actimed’s lead candidate, S-pindolol, is being developed as a novel therapy to address this unmet medical need. The collaboration is expected to accelerate access to advanced treatments in South Asia, while strengthening Mankind’s innovation-driven portfolio.  

 

Notable updates  

* Actimed Therapeutics signs licensing agreement with Mankind Pharma on November 21, 2025  

* Exclusive rights granted for India and South Asian territories  

* Focus on therapies for cancer cachexia and muscle-wasting disorders  

* Agreement covers patents, know-how, and future related developments  

* Partnership aims to expand access to innovative treatments in the region  

 

The licensing deal underscores the growing importance of cross-border collaborations in tackling critical health challenges, positioning Mankind Pharma as a key player in delivering advanced therapies for cachexia in South Asia.  

 

Sources: Manila Times, Pharmabiz, Business Standard